Upper Limb Muscle Spasticity – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Upper Limb Muscle Spasticity – Drugs In Development, 2024 report and make more profitable business decisions.
Spasms or spasticity is a condition in which the stiffening of muscles is seen. Upper limb muscle spasticity is a motor neuron syndrome of the upper extremities. This condition causes voluntary movement impairment following stroke, spinal cord injury, and paralysis. It commonly affects elbows, arms, forearms, wrists and is characterized by muscle stiffness, impaired movement, pain, and reduced ability to relax muscles. It commonly occurs in survivors of TBI and stroke. Based on physical examination and radiographic findings diagnosis is done. Physiotherapy like stretching, and pharmacological management with BoNT-A injection and by electrical stimulation of muscles.
The Upper Limb Muscle Spasticity drugs in development market research report provide comprehensive information on the therapeutics under development for Upper Limb Muscle Spasticity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Upper Limb Muscle Spasticity and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Upper Limb Muscle Spasticity | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Upper Limb Muscle Spasticity therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Upper Limb Muscle Spasticity pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Upper Limb Muscle Spasticity treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncCKD Bio Corp
Huons Co Ltd
Huons Global Co Ltd
Ipsen SA
Merz Pharma GmbH & Co KgaA
Revance Therapeutics Inc
Saol Therapeutics Inc
Shionogi & Co Ltd
Supernus Pharmaceuticals Inc
Viatris Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Upper Limb Muscle Spasticity reports